{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:03:12Z","timestamp":1785204192019,"version":"3.55.0"},"reference-count":28,"publisher":"Akademiai Kiado Zrt.","issue":"18","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"\u00d6sszefoglal\u00f3.<\/jats:bold>\n Bevezet\u00e9s:<\/jats:italic> Az endokrin betegs\u00e9gekhez t\u00e1rsul\u00f3 ovul\u00e1ci\u00f3s\n diszfunkci\u00f3 gyakori vezet\u0151 vagy t\u00e1rsul\u00f3 oka a n\u0151i infertilit\u00e1snak, de optim\u00e1lis\n reprodukci\u00f3s korban oki vagy ovul\u00e1ci\u00f3indukci\u00f3s kezel\u00e9ssel t\u00f6bbnyire rendezhet\u0151 a\n fertilit\u00e1s. Az in vitro<\/jats:italic> fertiliz\u00e1ci\u00f3s (IVF-) kezel\u00e9sek vezet\u0151\n indik\u00e1ci\u00f3i jelenleg az androl\u00f3giai \u00e9s a n\u0151i \u00e9letkorb\u00f3l ad\u00f3d\u00f3, petef\u00e9szek-eredet\u0171\n infertilit\u00e1s, de egy\u00e9b endokrin diszfunkci\u00f3 t\u00e1rsul\u00e1sa befoly\u00e1solja a kezel\u00e9si\n eredm\u00e9nyeket. C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Az endokrin betegs\u00e9gek gyakoris\u00e1g\u00e1nak\n vizsg\u00e1lata az IVF-programban r\u00e9szt vev\u0151 p\u00e1rok n\u0151tagjain\u00e1l.\n M\u00f3dszer:<\/jats:italic> Az IVF-program el\u0151tti alkalmass\u00e1gi vizsg\u00e1latok\n sor\u00e1n a vezet\u0151 indik\u00e1ci\u00f3t\u00f3l f\u00fcggetlen\u00fcl r\u00e9szletes endokrinol\u00f3giai kivizsg\u00e1l\u00e1st\n v\u00e9gezt\u00fcnk 231 n\u0151n\u00e9l (\u00e1tlag\u00e9letkor 34 \u00e9v). A vizsg\u00e1latok kiterjedtek a\n hypothalamus- \u00e9s petef\u00e9szek-funkci\u00f3ra, a pajzsmirigyfunkci\u00f3ra \u00e9s\n pajzsmirigy-autoimmunit\u00e1sra, a mell\u00e9kvese-funkci\u00f3ra, a sz\u00e9nhidr\u00e1t-anyagcser\u00e9re\n \u00e9s az inzulinrezisztenci\u00e1ra. Az egyes endokrin betegs\u00e9gek el\u0151fordul\u00e1s\u00e1n t\u00fal azok\n t\u00e1rsul\u00e1si gyakoris\u00e1g\u00e1t is elemezt\u00fck. Eredm\u00e9nyek:<\/jats:italic> Az IVF vezet\u0151\n javallatainak megoszl\u00e1sa megfelelt a nemzetk\u00f6zi tendenci\u00e1knak, endokrin jelleg\u0171\n volt 87 esetben (37,6%; cs\u00f6kkent petef\u00e9szek-tartal\u00e9k: 55 eset \u00e9s kr\u00f3nikus\n anovul\u00e1ci\u00f3: 32 eset). T\u00e1rsul\u00f3 endokrin elt\u00e9r\u00e9st 141 esetben tal\u00e1ltunk, \u00edgy\n \u00f6sszesen 161 n\u0151t \u00e9rintett az endokrin diszfunkci\u00f3 (69,7%; \u00e1tlag\u00e9letkor 35 \u00e9v).\n Az endokrin diszfunkci\u00f3k el\u0151fordul\u00e1sa gyakoris\u00e1gi sorrendben:\n pajzsmirigy-diszfunkci\u00f3 (32,5%), cs\u00f6kkent petef\u00e9szek-tartal\u00e9k (23,8%),\n pajzsmirigy-autoimmunit\u00e1s (22,5%), polycyst\u00e1s ovarium szindr\u00f3ma (15,6%),\n inzulinrezisztencia (22,5%), elh\u00edz\u00e1s (23,8%), hyperprolactinaemia (13,4%). Az\n endokrin betegs\u00e9gek t\u00e1rsul\u00e1sa minden k\u00f3rk\u00e9p eset\u00e9ben fellelhet\u0151 volt.\n Hypogonadotrop hypogonadismus 2, congenitalis adrenalis hyperplasia 1 esetben\n fordult el\u0151. Nem tal\u00e1ltunk endokrin elt\u00e9r\u00e9st 70 esetben (30,3%).\n K\u00f6vetkeztet\u00e9s:<\/jats:italic> Vizsg\u00e1latunk igazolja az endokrin\n diszfunkci\u00f3k halmozott megjelen\u00e9s\u00e9t \u00e9s gyakori t\u00e1rsul\u00e1s\u00e1t az IFV-program\n r\u00e9sztvev\u0151in\u00e9l, b\u00e1rmely indik\u00e1ci\u00f3 eset\u00e9n. A r\u00e9szletes endokrin kivizsg\u00e1l\u00e1s \u00e9s az\n IVF-kezel\u00e9st v\u00e9gz\u0151k endokrin j\u00e1rtass\u00e1ga hozz\u00e1j\u00e1rulhat az IVF-kezel\u00e9s\n sikeress\u00e9g\u00e9hez. Orv Hetil. 2022; 163(18): 712\u2013719.<\/jats:p>\n Summary.<\/jats:bold>\n Introduction:<\/jats:italic> Ovulatory dysfunction associated with endocrine\n diseases is a common leading or associated cause of female infertility, but at\n optimal reproductive age, causal or ovulation-induction treatment can usually\n settle fertility. The leading indications for in vitro<\/jats:italic>\n fertilization (IVF) treatments are currently andrological and originated from\n age-related ovarian infertility, but other accompanying endocrine dysfunctions\n affect treatment outcomes. Objective:<\/jats:italic> To investigate the\n incidence of endocrine diseases in female members of couples participating in\n IVF program. Method:<\/jats:italic> During aptitude tests prior to the IVF\n program, from the leading indication independently, a detailed endocrinological\n examination was performed in 231 women (mean age: 34 years). The studies of\n hypothalamic and ovarian function, thyroid function and thyroid autoimmunity,\n adrenal function, carbohydrate metabolism and insulin resistance were covered.\n In addition to the incidence of each endocrine disease, the frequency of their\n association was analyzed. Results:<\/jats:italic> The distribution of IVF lead\n indications was in line with the international trends, it was endocrine nature\n in 87 cases (37.6%; decreased ovarian reserve in 55 cases and chronic\n anovulation in 32 cases). Associated endocrine abnormalities were found in 141\n cases, and a total of 161 women was affected by endocrine dysfunction (69.7%;\n mean age: 35 years). Endocrine dysfunction incidences in order of frequency were\n thyroid dysfunction (32.5%), diminished ovarian reserve (23.8%), thyroid\n autoimmunity (22.5%), polycystic ovarian syndrome (15.6%), insulin resistance\n (22.5%), obesity (23.8%), hyperprolactinemia (13.4%). The endocrine disease\n associations were found in all of the cases above. Hypogonadotropic hypogonadism\n occurred in 2 cases, congenital adrenal hyperplasia occurred in 1 case. No\n endocrine abnormalities were found in 70 cases (30.3%).\n Conclusion:<\/jats:italic> Our study confirms the cumulative appearance of\n endocrine dysfunctions and frequent association in IVF participants with any\n lead indication. The detailed endocrine examination and proficiency\/skill in\n reproductive endocrinology of IVF practitioners may contribute to IVF treatment\n success. Orv Hetil. 2022; 163(18): 712\u2013719.<\/jats:p>","DOI":"10.1556\/650.2022.32372","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T16:41:44Z","timestamp":1668789704000},"page":"712-719","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":5,"title":["Endokrin k\u00f3rk\u00e9pek el\u0151fordul\u00e1sa \u00e9s t\u00e1rsul\u00e1sa in vitro fertiliz\u00e1ci\u00f3s programban r\u00e9szt vev\u0151 n\u0151k k\u00f6r\u00e9ben"],"prefix":"10.1556","volume":"163","author":[{"given":"T\u00fcnde","family":"Herman","sequence":"first","affiliation":[{"name":"Debreceni Egyetem, Klinikai K\u00f6zpont, Assziszt\u00e1lt Reprodukci\u00f3s Centrum Debrecen Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Csehely","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Sz\u00fcl\u00e9szeti \u00e9s N\u0151gy\u00f3gy\u00e1szati Int\u00e9zet Debrecen, Egyetem t\u00e9r 1., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Orosz","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Sz\u00fcl\u00e9szeti \u00e9s N\u0151gy\u00f3gy\u00e1szati Int\u00e9zet Debrecen, Egyetem t\u00e9r 1., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harjit Pal","family":"Bhattoa","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Laborat\u00f3riumi Medicina Int\u00e9zet Debrecen Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Deli","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Sz\u00fcl\u00e9szeti \u00e9s N\u0151gy\u00f3gy\u00e1szati Int\u00e9zet Debrecen, Egyetem t\u00e9r 1., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Sz\u00fcl\u00e9szeti \u00e9s N\u0151gy\u00f3gy\u00e1szati Int\u00e9zet Debrecen, Egyetem t\u00e9r 1., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Jakab","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Sz\u00fcl\u00e9szeti \u00e9s N\u0151gy\u00f3gy\u00e1szati Int\u00e9zet Debrecen, Egyetem t\u00e9r 1., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 Ministry of Human Resources. Guideline for the evaluation of infertility and subfertility, and of the asssited reproductive technologies. [Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelve az infertilitas \u00e9s subfertilitas kivizsg\u00e1l\u00e1s\u00e1r\u00f3l \u00e9s az assziszt\u00e1lt reprodukci\u00f3s kezel\u00e9sekr\u0151l.] E\u00fc K\u00f6zl. 2021; (LXXI)4: 399-441. [Hungarian] Available from: http:\/\/www.kozlonyok.hu\/kozlonyok\/Kozlonyok\/6\/PDF\/2021\/4.pdf [accessed: October 15, 2021]."},{"key":"ref1","unstructured":"2 Taylor HS, Pal L, Seli E. (eds.) Speroff's clinical gynecologic endocrinology and infertility. 9th edn. Lippincott Williams and Wilkins, Philadelphia, PA, 2019."},{"key":"ref2","unstructured":"3 Strauss III JF, Barbieri RL, Yen SS. (eds.) Yen and Yaffe's Reproductive endocrinology: physiology, pathophysiology, and clinical management. 8th edn. Elsevier, Philadelphia, PA, 2019."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Devine K, Mumford SL, Wu M, et al. Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertil Steril. 2015; 104: 612-619. e3.","DOI":"10.1016\/j.fertnstert.2015.05.017"},{"key":"ref4","unstructured":"5 Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2015: assisted reproductive technology, national summary report. US Dept of Health and Human Services, Atlanta, GA, 2017."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1089\/thy.2006.0235","article-title":"Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002)","volume":"17","author":"6 Aoki","year":"2007","unstructured":"6 Aoki Y, Belin RM, Clickner R, et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007; 17: 1211-1223.","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review","volume":"94","author":"7 Golden","year":"2009","unstructured":"7 Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009; 94: 1853-1878.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1210\/jcem.87.7.8678","article-title":"Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies","volume":"87","author":"8 Huber","year":"2002","unstructured":"8 Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002; 87: 3221-3226.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: scientific review and guidelines for diagnosis and management","volume":"291","author":"9 Surks","year":"2004","unstructured":"9 Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238.","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/humupd\/dmw003","article-title":"Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review","volume":"22","author":"10 van den Boogaard","year":"2016","unstructured":"10 van den Boogaard E, Vissenberg R, Land JA, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update 2016; 22: 532-533.","journal-title":"Hum Reprod Update"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/humupd\/dmw019","article-title":"The impact of thyroid autoimmunity on IVF\/ICSI outcome: a systematic review and meta-analysis","volume":"22","author":"11 Busnelli","year":"2016","unstructured":"11 Busnelli A, Paffoni A, Fedele L, et al. The impact of thyroid autoimmunity on IVF\/ICSI outcome: a systematic review and meta-analysis. Hum Reprod Update 2016; 22: 775-790.","journal-title":"Hum Reprod Update"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12958-020-00671-3","article-title":"Thyroid autoimmunity and IVF\/ICSI outcomes in euthyroid women: a systematic review and meta-analysis","volume":"18","author":"12 Venables","year":"2020","unstructured":"12 Venables A, Wong W, Way M, et al. Thyroid autoimmunity and IVF\/ICSI outcomes in euthyroid women: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2020; 18: 120.","journal-title":"Reprod Biol Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"13 Azziz","year":"2016","unstructured":"13 Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057.","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1210\/jc.83.9.3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study","volume":"83","author":"14 Knochenhauer","year":"1998","unstructured":"14 Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83: 3078-3082.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"15 Yildiz","year":"2012","unstructured":"15 Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27: 3067-3073.","journal-title":"Hum Reprod"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Poppe K, Bisschop P, Fugazzola L, et al. 2021 European Thyroid Association guideline on thyroid disorders prior to and during assisted reproduction. Eur Thyroid J. 2021; 9: 281-295. [Erratum: Eur Thyroid J. 2021; 10: 268.]","DOI":"10.1159\/000512790"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1056\/NEJMcp1611144","article-title":"Subclinical hypothyroidism","volume":"376","author":"17 Peeters","year":"2017","unstructured":"17 Peeters RP. Subclinical hypothyroidism. N Engl J Med. 2017; 376: 2556-2565.","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Litwicka K, Arrivi C, Varricchio MT, et al. In women with thyroid autoimmunity, does low-dose prednisolone administration, compared with no adjuvant therapy, improve in vitro fertilization clinical results? J Obstet Gynaecol Res. 2015; 41: 722-728.","DOI":"10.1111\/jog.12615"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-47.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Legro RS, Arslanian SA, Ehrmann DA, et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98: 4565-4592. [Erratum: J Clin Endocrinol Metab. 2021; 106: e2462.]","DOI":"10.1210\/jc.2013-2350"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33: 1602-1618. Correction: Hum Reprod. 2019; 34: 388.","DOI":"10.1093\/humrep\/dey363"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"22 Ferraretti","year":"2011","unstructured":"22 Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26: 1616-1624.","journal-title":"Hum Reprod"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.fertnstert.2010.08.047","article-title":"Age-related normogram for antral follicle count: McGill reference guide","volume":"95","author":"23 Almog","year":"2011","unstructured":"23 Almog B, Shehata F, Shalom-Paz E, et al. Age-related normogram for antral follicle count: McGill reference guide. Fertil Steril. 2011; 95: 663-666.","journal-title":"Fertil Steril"},{"key":"ref23","unstructured":"24 Fritz MA, Speroff L. (eds.) Clinical gynecologic endocrinology and infertility. 8th edn. Wolters Kluwer\/Lippincott Williams & Wilkins, Philadelphia, PA, 2011."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/humupd\/dmz014","article-title":"The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis","volume":"25","author":"25 Shigesi","year":"2019","unstructured":"25 Shigesi N, Kvaskoff M, Kirtley S, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update 2019; 25: 486-503.","journal-title":"Hum Reprod Update"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1530\/EC-18-0309","article-title":"Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis","volume":"7","author":"26 Romitti","year":"2018","unstructured":"26 Romitti M, Fabris VC, Ziegelmann PK, et al. Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis. Endocr Connect. 2018; 7: 1158-1167.","journal-title":"Endocr Connect"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12884-018-1783-4","article-title":"Changes in serum prolactin level during intracytoplasmic sperm injection, and effect on clinical pregnancy rate: a prospective observational study","volume":"18","author":"27 Kamel","year":"2018","unstructured":"27 Kamel A, Halim AA, Shehata M, et al. Changes in serum prolactin level during intracytoplasmic sperm injection, and effect on clinical pregnancy rate: a prospective observational study. BMC Pregnancy Childbirth 2018; 18: 141.","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28 Herman T, T\u00f6r\u00f6k P, Lagan\u00e0 AS, et al. In vitro fertilization treatment of a patient with primary partial empty sella and other co-factors. Obstet Gynecol Cases Rev. 2020; 7: 174.","DOI":"10.23937\/2377-9004\/1410174"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/18\/article-p712.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/18\/article-p712.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/18\/article-p712.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T15:23:27Z","timestamp":1698247407000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/18\/article-p712.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":28,"journal-issue":{"issue":"18"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32372","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}